Literature DB >> 23653350

Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.

Nikolas Balanis1, Michael K Wendt, Barbara J Schiemann, Zhenghe Wang, William P Schiemann, Cathleen R Carlin.   

Abstract

We previously established that overexpression of the EGF receptor (EGFR) is sufficient to induce tumor formation by otherwise nontransformed mammary epithelial cells, and that the initiation of epithelial-mesenchymal transition (EMT) is capable of increasing the invasion and metastasis of these cells. Using this breast cancer (BC) model, we find that in addition to EGF, adhesion to fibronectin (FN) activates signal transducer and activator of transcription 3 (STAT3) through EGFR-dependent and -independent mechanisms. Importantly, EMT facilitated a signaling switch from SRC-dependent EGFR:STAT3 signaling in pre-EMT cells to EGFR-independent FN:JAK2:STAT3 signaling in their post-EMT counterparts, thereby sensitizing these cells to JAK2 inhibition. Accordingly, human metastatic BC cells that failed to activate STAT3 downstream of EGFR did display robust STAT3 activity upon adhesion to FN. Furthermore, FN enhanced outgrowth in three-dimensional organotypic cultures via a mechanism that is dependent upon β1 integrin, Janus kinase 2 (JAK2), and STAT3 but not EGFR. Collectively, our data demonstrate that matrix-initiated signaling is sufficient to drive STAT3 activation, a reaction that is facilitated by EMT during BC metastatic progression.

Entities:  

Keywords:  Breast Cancer; Epidermal Growth Factor Receptor (EGFR); Epithelial to Mesenchymal Transition; Fibronectin; Integrin; JAK2; STAT3

Mesh:

Substances:

Year:  2013        PMID: 23653350      PMCID: PMC3689941          DOI: 10.1074/jbc.M113.475277

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  EGF-induced activation of Stat1, Stat3, and Stat5b is unrelated to the stimulation of DNA synthesis in cultured hepatocytes.

Authors:  T K Guren; H Abrahamsen; G H Thoresen; E Babaie; T Berg; T Christoffersen
Journal:  Biochem Biophys Res Commun       Date:  1999-05-19       Impact factor: 3.575

2.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 3.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

Review 4.  Signal co-operation between integrins and other receptor systems.

Authors:  Charles H Streuli; Nasreen Akhtar
Journal:  Biochem J       Date:  2009-03-15       Impact factor: 3.857

Review 5.  IL-6 signal transduction and its physiological roles: the signal orchestration model.

Authors:  D Kamimura; K Ishihara; T Hirano
Journal:  Rev Physiol Biochem Pharmacol       Date:  2003-04-05       Impact factor: 5.545

6.  TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer.

Authors:  M K Wendt; B J Schiemann; J G Parvani; Y-H Lee; Y Kang; W P Schiemann
Journal:  Oncogene       Date:  2012-06-18       Impact factor: 9.867

Review 7.  Role of transforming growth factor-beta in cancer progression.

Authors:  Amy J Galliher; Jason R Neil; William P Schiemann
Journal:  Future Oncol       Date:  2006-12       Impact factor: 3.404

8.  Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor.

Authors:  Hong-Jun Liao; Graham Carpenter
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

9.  Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.

Authors:  Robert X-D Song; Yuchai Chen; Zhenguo Zhang; Yongde Bao; Wei Yue; Ji-Ping Wang; Ping Fan; Richard J Santen
Journal:  J Steroid Biochem Mol Biol       Date:  2009-10-06       Impact factor: 4.292

10.  A leucine-based determinant in the epidermal growth factor receptor juxtamembrane domain is required for the efficient transport of ligand-receptor complexes to lysosomes.

Authors:  S J Kil; M Hobert; C Carlin
Journal:  J Biol Chem       Date:  1999-01-29       Impact factor: 5.157

View more
  54 in total

Review 1.  Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer.

Authors:  Nikolas Balanis; Cathleen R Carlin
Journal:  Mol Cell Endocrinol       Date:  2017-01-12       Impact factor: 4.102

Review 2.  Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition.

Authors:  Reem Malek; Hailun Wang; Kekoa Taparra; Phuoc T Tran
Journal:  Cells Tissues Organs       Date:  2017-02-20       Impact factor: 2.481

Review 3.  Dynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironment.

Authors:  Spiros A Vlahopoulos; Osman Cen; Nina Hengen; James Agan; Maria Moschovi; Elena Critselis; Maria Adamaki; Flora Bacopoulou; John A Copland; Istvan Boldogh; Michael Karin; George P Chrousos
Journal:  Cytokine Growth Factor Rev       Date:  2015-06-20       Impact factor: 7.638

Review 4.  Fibronectin in malignancy: Cancer-specific alterations, protumoral effects, and therapeutic implications.

Authors:  Jonathan W Rick; Ankush Chandra; Cecilia Dalle Ore; Alan T Nguyen; Garima Yagnik; Manish K Aghi
Journal:  Semin Oncol       Date:  2019-08-27       Impact factor: 4.929

5.  Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.

Authors:  Jenny G Parvani; Maneesh D Gujrati; Margaret A Mack; William P Schiemann; Zheng-Rong Lu
Journal:  Cancer Res       Date:  2015-04-09       Impact factor: 12.701

6.  Cucurbitacin I inhibits STAT3, but enhances STAT1 signaling in human cancer cells in vitro through disrupting actin filaments.

Authors:  Hui Guo; Shan Kuang; Qiao-Ling Song; Man Liu; Xiao-Xiao Sun; Qiang Yu
Journal:  Acta Pharmacol Sin       Date:  2017-11-09       Impact factor: 6.150

7.  Selective Inhibition of STAT3 Phosphorylation Using a Nuclear-Targeted Kinase Inhibitor.

Authors:  Matthew D Bartolowits; Wells Brown; Remah Ali; Anthony M Pedley; Qingshou Chen; Kyle E Harvey; Michael K Wendt; Vincent Jo Davisson
Journal:  ACS Chem Biol       Date:  2017-08-18       Impact factor: 5.100

8.  TGF-β1 mediates estrogen receptor-induced epithelial-to-mesenchymal transition in some tumor lines.

Authors:  Dong-Mei Fan; Peng-Wei Qi; She-Gan Gao; Ya-Wei Chen; Xiao-Lin Cheng
Journal:  Tumour Biol       Date:  2014-08-13

9.  Fibronectin induces epithelial-mesenchymal transition in human breast cancer MCF-7 cells via activation of calpain.

Authors:  Cheng-Lin Li; Dan Yang; Xin Cao; Fan Wang; Duan-Yang Hong; Jing Wang; Xiang-Chun Shen; Yan Chen
Journal:  Oncol Lett       Date:  2017-03-23       Impact factor: 2.967

10.  Cross talk between the TM4SF5/focal adhesion kinase and the interleukin-6/STAT3 pathways promotes immune escape of human liver cancer cells.

Authors:  Jihye Ryu; Minkyung Kang; Mi-Sook Lee; Hye-Jin Kim; Seo Hee Nam; Haeng Eun Song; Doohyung Lee; Jung Weon Lee
Journal:  Mol Cell Biol       Date:  2014-06-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.